Hervé Hoppenot

Chairman, President, and CEO at Incyte Corp

Board

Since January 2014

Age

65 years

Education

Holds a Diploma from ESSEC International Business School.

Tenure

Joined Incyte in January 2014 as President and Chief Executive Officer and was promoted to Chairman of the Board in May 2015.

Also at Incyte Corp

Christiana Stamoulis

EVP and CFO

Lee Heeson

EVP, Incyte International

Matteo Trotta

EVP and General Manager, Dermatology US

About

A seasoned executive in the pharmaceutical and biotechnology industries, his career spans several decades in which he held senior leadership roles at major companies. His early experiences include key positions at firms such as Aventis and Novartis, where he oversaw global marketing, product strategy, and oncology operations.

His transition into Incyte marked a significant step in his career, as he joined the company in January 2014 and quickly established a strong leadership presence. At Incyte, his strategic vision has been instrumental in advancing innovative therapies, particularly in oncology and hematology. His career progression highlights a commitment to excellence and transformative impact in the biopharmaceutical space.

Beyond his executive roles, his contributions extend to board service at companies like Cellectis S.A., underscoring his versatility and deep industry insight. His leadership has not only driven corporate growth but has also positioned the company as a key player in advancing breakthrough treatments.

$INCY Performance Under Hervé Hoppenot

Past Roles

Organization	Role	Date Range	Details
Novartis Pharmaceuticals Corporation	President of Novartis Oncology	January 2010 – January 2014	N/A
Novartis Pharmaceuticals Corporation	Executive Vice President, Chief Commercial Officer of Novartis Oncology & Head of Global Product Strategy & Scientific Development	September 2006 – January 2010	N/A
Novartis Pharmaceuticals Corporation	Senior Vice President, Head of Global Marketing of Novartis Oncology	2003 – September 2006	N/A
Aventis S.A. (formerly Rhône-Poulenc S.A.)	Vice President Oncology U.S. of Aventis Pharmaceuticals, Inc.	2000 – 2003	N/A
Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Vice President U.S. Oncology Operations	1998 – 2000	N/A

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,296,666	Annual	Fixed annual salary for 2023.
All Other Compensation	$53,187	Annual	Includes Life Insurance Premiums ($7,524 ), Financial Planning Services ($22,948 which includes $7,948 tax gross-up), Statutory Fee for EU Subsidiary ($4,400 ); Travel Reimbursement: Not applicable.

Performance Compensation

Data from FY 2023

Non-Equity Incentive Plan Compensation

Metric	Value	Details
Threshold Payout	$1,048,354	Minimum performance payout level.
Target Payout	$1,426,333	Expected performance payout level.
Maximum Payout	$2,881,192	Maximum possible payout based on performance.
Actual Payout (2023)	$1,554,703	Achieved payout reflecting a 109% overall multiplier applied to the 110% target bonus.
Performance Metrics	Corporate Objectives	Tied to Discovery, Clinical Development, ESG, and Global Commercial objectives with additional bonus percentages of 10% (Discovery), 15% (Clinical Development), 10% (Global Commercial), and 5% (Business Development).
Evaluation Period	2023	Annual performance evaluation.
Vesting Schedule	N/A	Cash-based annual bonus not subject to vesting.

Stock Awards

Grant Date	Grant Date Fair Value	Grant Date Stock Price	Shares/Units	Performance Metrics & Targets	Vesting Schedule
Jan 20, 2023	$2,413,361	$83.20	N/A	No specific performance metrics detailed for this tranche.	N/A
Jul 14, 2023	$2,011,692	$61.76	N/A	Performance shares subject to percentage multipliers: 75% (Threshold), 100% (Target), and 150% (Max) based on meeting development, relative TSR, and revenue-based goals; Evaluation period ends Dec 31, 2025.	Vests on the third anniversary of the grant date, subject to continued service.

Note: For Option Awards, no detailed performance metrics or targets were provided in the documents for 2023.